Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys and GeneFrontier Pen Marketing Collaboration

NEW YORK, Sept. 24 (GenomeWeb News) - MorphoSys of Munich and GeneFrontier of Tokyo will co-market MorphoSys' human antibody technology in Japan, the companies said yesterday.

 

Under the multi-year agreement, the two companies will market MorphoSys' Human Combinatorial Antibody Library technology in Japanfor both research and therapeutic applications. The deal is part of MorphoSys' effort to expand into new geographic markets.

 

As part of an ongoing pre-marketing agreement, MorphoSys and GeneFrontier have already conducted several research projects with Japanese partners.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

Higher polygenic risk scores for attention-deficit/hyperactivity disorder were also linked to cognitive decline and Alzheimer's disease risk, according to a new study in Molecular Psychiatry.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.